Feature

Approval of COVID-19 vaccines will change nature of clinical trials


 

‘A lot of redundancy’

Dr. Alexander emphasized that any safety or efficacy issues with the first COVID-19 vaccines must be identified before the vaccine is offered to a large portion of the U.S. population.

“While the data from the Pfizer and Moderna trials are said to be favorable, we at IDSA want to make sure that whatever vaccine comes to market is safe,” she said. “Having an unsafe vaccine on the market would be worse than no vaccine, because you’re compromising the public confidence. We have to make sure the public trusts the process and that sufficient data have been evaluated to ensure the vaccine is safe and efficacious.

“I believe the FDA is being very careful and thoughtful in [its] response,” Dr. Alexander said. “They realize how important it is to get a vaccine and save lives. While they’re doing things differently and moving much faster than before, they’re still trying to be thoughtful and reasonable. They don’t seem to be putting people at risk or circumventing the regulatory standards.”

Moreover, she pointed out, the FDA’s Vaccines and Related Biological Products Advisory Committee, which is expected to meet on Dec. 10, will review the trial data before the agency grants an EUA to Pfizer or Moderna. Then the FDA will post the data publicly.

The next step is for the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention to look at the data and decide who in the United States should receive the vaccine first, she pointed out. And both Pfizer and Moderna have shown their data to advisory panels of outside experts.

“There’s a lot of redundancy, and a lot of people are looking at the data,” Dr. Alexander said. “So I don’t think we’re cutting corners to get it out there more quickly.”

A version of this article originally appeared on Medscape.com.

Pages

Recommended Reading

FDA authorizes baricitinib combo for COVID-19
MDedge Psychiatry
Tips for physicians, patients to make the most of the holidays amid COVID
MDedge Psychiatry
Pfizer files for FDA emergency use authorization of COVID vaccine
MDedge Psychiatry
Antidepressant shows early promise for mild COVID-19
MDedge Psychiatry
AMA takes on vaccine misinformation, physician vaccines, racism
MDedge Psychiatry
2020 and the telehealth boom
MDedge Psychiatry
A call to make four telehealth provisions permanent
MDedge Psychiatry
Telepsychiatry poised to thrive after the pandemic
MDedge Psychiatry
COVID-19 cases in children continue to set records
MDedge Psychiatry
CDC panel delves into priorities for COVID vaccine distribution
MDedge Psychiatry